Plain-English translation of NCT06643286 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a smartphone app called the Digizorg Melanoma app, designed specifically for people who have been treated for early-stage melanoma (stage I or II). The app provides personalized information about your diagnosis, the treatment you received, what to expect during follow-up, and support resources. Researchers want to see whether using this app helps you feel more in control of your health and more confident managing your care after treatment.
After melanoma treatment, many survivors feel uncertain about what to watch for, when to have follow-up appointments, and where to find support. This trial exists because doctors and patients believe that having access to personalized, easy-to-understand information tailored to each person's specific situation could help survivors feel less anxious and more equipped to manage their health.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to either receive the personalized app along with your regular care, or to continue with regular care alone. Over 12 months, you will complete questionnaires at the start, at 6 months, and at 12 months asking about how empowered you feel, your confidence in managing your care, any fears about cancer returning, and your satisfaction with the information and support you receive. Researchers will also review your medical records to see how often you visit the hospital or doctor.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Netherlands